ATE467632T1 - Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors - Google Patents

Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors

Info

Publication number
ATE467632T1
ATE467632T1 AT06830424T AT06830424T ATE467632T1 AT E467632 T1 ATE467632 T1 AT E467632T1 AT 06830424 T AT06830424 T AT 06830424T AT 06830424 T AT06830424 T AT 06830424T AT E467632 T1 ATE467632 T1 AT E467632T1
Authority
AT
Austria
Prior art keywords
pyrroloä2
büpyridine
modulators
receptor
derivatives
Prior art date
Application number
AT06830424T
Other languages
English (en)
Inventor
Matthias Nettekoven
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE467632T1 publication Critical patent/ATE467632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06830424T 2005-12-16 2006-12-06 Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors ATE467632T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112317 2005-12-16
PCT/EP2006/069390 WO2007068641A1 (en) 2005-12-16 2006-12-06 Pyrrolo [2 , 3-b] pyridine derivatives as h3 receptor modulators

Publications (1)

Publication Number Publication Date
ATE467632T1 true ATE467632T1 (de) 2010-05-15

Family

ID=37698129

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06830424T ATE467632T1 (de) 2005-12-16 2006-12-06 Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors

Country Status (13)

Country Link
US (1) US7351708B2 (de)
EP (1) EP1971605B1 (de)
JP (1) JP2009519293A (de)
KR (1) KR101015666B1 (de)
CN (1) CN101331131A (de)
AT (1) ATE467632T1 (de)
AU (1) AU2006326067A1 (de)
BR (1) BRPI0619985A2 (de)
CA (1) CA2631695A1 (de)
DE (1) DE602006014305D1 (de)
ES (1) ES2344077T3 (de)
IL (1) IL191763A0 (de)
WO (1) WO2007068641A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR074466A1 (es) * 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
AR074467A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Tetrahidropiran espiro pirrolidinonas y piperidinonas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento y/o prevencion de enfermedades del snc ,tales como alzheimer y parkinson, entre otras.
US8222416B2 (en) * 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN102952139B (zh) * 2011-08-30 2016-08-10 上海药明康德新药开发有限公司 反式-3a-氟吡咯烷[3,4-C]并环化合物及其制备方法
MX364895B (es) 2013-03-13 2019-05-10 Forma Therapeutics Inc Nuevos compuestos y composiciones para la inhibicion de fasn.
KR102161787B1 (ko) * 2018-07-02 2020-10-06 한국기초과학지원연구원 수면 장애의 예방 또는 치료용 약학적 조성물
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
GB9902047D0 (en) 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
WO2004032874A2 (en) * 2002-10-09 2004-04-22 Scios Inc. AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP1636224B1 (de) * 2003-05-21 2010-07-14 Prosidion Limited Pyrrolopyridin-2-carbonsäuren als hemmer der glycogenphosphorylase
CA2561628C (en) 2004-04-01 2012-05-08 Eli Lilly And Company Histamine h3 receptor agents, preparation and therapeutic uses

Also Published As

Publication number Publication date
US20070142358A1 (en) 2007-06-21
KR101015666B1 (ko) 2011-02-22
CN101331131A (zh) 2008-12-24
ES2344077T3 (es) 2010-08-17
IL191763A0 (en) 2008-12-29
EP1971605B1 (de) 2010-05-12
WO2007068641A1 (en) 2007-06-21
KR20080068132A (ko) 2008-07-22
JP2009519293A (ja) 2009-05-14
EP1971605A1 (de) 2008-09-24
US7351708B2 (en) 2008-04-01
AU2006326067A1 (en) 2007-06-21
BRPI0619985A2 (pt) 2011-10-25
DE602006014305D1 (de) 2010-06-24
CA2631695A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
TW200738651A (en) Cyclohexyl sulfonamide derivatives
TW200612936A (en) Indole derivatives
NO20082096L (no) Azaindol-2-karboksamidderivativer
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
TW200616953A (en) Indole, indazole or indoline derivatives
GB0510143D0 (en) Novel compounds A1
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
DE602007011434D1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину
ATE412636T1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
TW200637817A (en) 5-aminoindole derivatives
ATE481395T1 (de) Cyclohexylderivate
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
ATE479691T1 (de) 4,5,6,7-tetrahydrothienoä2,3-cüpyridine als h3- modulatoren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1971605

Country of ref document: EP